Log in

CVE:COTCotinga Pharmaceuticals Stock Price, Forecast & News

C$0.04
-0.01 (-12.50 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.04
Now: C$0.04
C$0.04
50-Day Range
C$0.03
MA: C$0.04
C$0.05
52-Week Range
C$0.02
Now: C$0.04
C$0.37
Volume2,000 shs
Average Volume23,553 shs
Market CapitalizationC$769,510.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-519-8585157

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC($0.18) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$769,510.00
Next Earnings Date9/2/2020 (Estimated)
OptionableOptionable

Receive COT News and Ratings via Email

Sign-up to receive the latest news and ratings for COT and its competitors with MarketBeat's FREE daily newsletter.

Cotinga Pharmaceuticals (CVE:COT) Frequently Asked Questions

How has Cotinga Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cotinga Pharmaceuticals' stock was trading at C$0.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, COT stock has increased by 16.7% and is now trading at C$0.04. View which stocks have been most impacted by Coronavirus.

When is Cotinga Pharmaceuticals' next earnings date?

Cotinga Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, September 2nd 2020. View our earnings forecast for Cotinga Pharmaceuticals.

Has Cotinga Pharmaceuticals been receiving favorable news coverage?

Media stories about COT stock have trended negative on Saturday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cotinga Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the next few days. View the latest news about Cotinga Pharmaceuticals.

Who are some of Cotinga Pharmaceuticals' key competitors?

What other stocks do shareholders of Cotinga Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals investors own include Primo Water (PRMW), Cascades (CAS), Aurora Cannabis (ACB), Advantage Lithium (AAL), InPlay Oil (IPO), Harvest One Cannabis (HVT), Exchange Income (EIF), Datametrex AI (DM), Canadian National Railway (CNI) and Alimentation Couche-Tard (ATD.B).

Who are Cotinga Pharmaceuticals' key executives?

Cotinga Pharmaceuticals' management team includes the following people:
  • Ms. Alison D. Silva, CEO, Pres & Director
  • Dr. Richard T. Ho, Chief Scientific Officer (Age 56)
  • Mr. Victor Hugo, Chief Financial Officer (Age 51)
  • Ms. Debi Sanderson MBA, Director of Resourcing & Operations
  • Mr. Paul Papi, VP of Investor Relations

What is Cotinga Pharmaceuticals' stock symbol?

Cotinga Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "COT."

How do I buy shares of Cotinga Pharmaceuticals?

Shares of COT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Cotinga Pharmaceuticals' stock price today?

One share of COT stock can currently be purchased for approximately C$0.04.

How big of a company is Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals has a market capitalization of C$769,510.00.

What is Cotinga Pharmaceuticals' official website?

The official website for Cotinga Pharmaceuticals is cotingapharma.com.

How can I contact Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals' mailing address is 100 Collip Cir Suite 230B, LONDON, ON N6G 4X8, Canada. The company can be reached via phone at +1-519-8585157.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.